Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy

K. Koubský

. 2024 ; 73 (Suppl. 2) : S597-S613. [pub] 20241129

Status minimální Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25005524

Chronic heart failure (CHF) is a rare entity in children but carries a burden of high mortality and morbidity. Medical treatment of pediatric CHF is largely based on guidelines for the adult population. In contrast to adults, evidence for the efficacy of medications in treating CHF in children is sparse. This may be due to the difficulty of conducting high-powered studies in children or to true differences in the mechanisms of CHF pathophysiology. Recent observations suggest that CHF in children differs from adults at the molecular and cellular levels. Different pathways are involved, leading to less fibrosis and hypertrophy than in adults, with potential implications for therapy. The main pathophysiological goals of medical treatment of pediatric CHF due to systemic left ventricular dysfunction are discussed in this review. These include preload and afterload optimization, diminishing cardiomyocyte apoptosis and necrosis as well as interstitial fibrosis, and optimizing myocardial oxygen consumption. The pediatric myocardium should be provided with optimal conditions to achieve its regenerative potential. The cornerstones of medical CHF therapy are angiotensin converting enzyme inhibitors (ACEI), beta blockers and mineralocorticoid receptor antagonists. There are potential benefits of tissue ACEI and ?1-selective beta blockers in children. Angiotensin receptor blockers are an alternative to ACEI and their slightly different mechanism of action may confer certain advantages and disadvantages. Diuretics are employed to achieve a euvolemic state. Digoxin is used more frequently in children than in adults. Promising new drugs already routinely used in adults include angiotensin receptor-neprilysin inhibitors and sodium-glucose contransporter 2 inhibitors. Key words: Pediatric heart failure, Heart failure with reduced ejection fraction (HFrEF), ACE inhibitor, Beta blocker, Digoxin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25005524
003      
CZ-PrNML
005      
20250312151250.0
007      
ta
008      
250213s2024 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.935438 $2 doi
035    __
$a (PubMed)39589305
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Koubský, K $u Children's Heart Centre, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic. karel.koubsky@fnmotol.cz
245    10
$a Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy / $c K. Koubský
520    9_
$a Chronic heart failure (CHF) is a rare entity in children but carries a burden of high mortality and morbidity. Medical treatment of pediatric CHF is largely based on guidelines for the adult population. In contrast to adults, evidence for the efficacy of medications in treating CHF in children is sparse. This may be due to the difficulty of conducting high-powered studies in children or to true differences in the mechanisms of CHF pathophysiology. Recent observations suggest that CHF in children differs from adults at the molecular and cellular levels. Different pathways are involved, leading to less fibrosis and hypertrophy than in adults, with potential implications for therapy. The main pathophysiological goals of medical treatment of pediatric CHF due to systemic left ventricular dysfunction are discussed in this review. These include preload and afterload optimization, diminishing cardiomyocyte apoptosis and necrosis as well as interstitial fibrosis, and optimizing myocardial oxygen consumption. The pediatric myocardium should be provided with optimal conditions to achieve its regenerative potential. The cornerstones of medical CHF therapy are angiotensin converting enzyme inhibitors (ACEI), beta blockers and mineralocorticoid receptor antagonists. There are potential benefits of tissue ACEI and ?1-selective beta blockers in children. Angiotensin receptor blockers are an alternative to ACEI and their slightly different mechanism of action may confer certain advantages and disadvantages. Diuretics are employed to achieve a euvolemic state. Digoxin is used more frequently in children than in adults. Promising new drugs already routinely used in adults include angiotensin receptor-neprilysin inhibitors and sodium-glucose contransporter 2 inhibitors. Key words: Pediatric heart failure, Heart failure with reduced ejection fraction (HFrEF), ACE inhibitor, Beta blocker, Digoxin.
650    _2
$a lidé $7 D006801
650    12
$a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
650    _2
$a dítě $7 D002648
650    _2
$a chronická nemoc $7 D002908
650    _2
$a inhibitory ACE $x terapeutické užití $7 D000806
650    _2
$a věkové faktory $7 D000367
650    _2
$a beta blokátory $x terapeutické užití $7 D000319
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 73, Suppl. 2 (2024), s. S597-S613
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39589305 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y - $z 0
990    __
$a 20250213 $b ABA008
991    __
$a 20250312151257 $b ABA008
999    __
$a min $b bmc $g 2283560 $s 1242544
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 73 $c Suppl. 2 $d S597-S613 $e 20241129 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
LZP    __
$a Pubmed-20250213

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...